SUPERNUS PHARMACEUTICALS INC (SUPN)
Health Care · Biopharmaceutical - Central Nervous System Therapeutics · NASDAQ
Supernus is a biopharmaceutical company commercializing approved CNS treatments across ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine while advancing a pipeline of novel neuropsychiatric therapies.
What SUPERNUS PHARMACEUTICALS INC does
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. The company markets approved products for ADHD, Parkinson's disease dyskinesia and hypomobility, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea, while advancing a pipeline of novel CNS product candidates. In July 2025, the company completed its acquisition of Sage Therapeutics to expand its CNS portfolio, including the postpartum depression treatment ZURZUVAE.
Themes: ["ADHD treatments","Parkinson's disease","Postpartum depression / maternal health","Epilepsy and seizure disorders","Migraine management","Movement disorders","CNS / neuroscience"]
Fundamentals
- Price$48.75 as of 2026-07-09 close
- Market cap$2.9B as of 2026-07-10
- 1-year return+49.2% as of 2026-07-09 close
- Net margin-3.7% as of 2026-07-10
- Gross margin+89.7% as of 2026-07-10
- ROE-2.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+16.3% as of 2026-07-10
- Revenue CAGR (3y)+2.5% SEC XBRL
- Beta0.57 as of 2026-07-10
Key risks (from latest filing)
["Dependence on commercial success of newly acquired ZURZUVAE; contingent consideration of up to $234 million based on achieving specific postpartum depression net sales targets through 2030","Significant operating losses and negative net margin (-3.74%) despite revenue growth; company remains unprofitable as of latest quarter","Competition from established pharmaceutical companies and other CNS-focused biotech firms in large markets like ADHD and epilepsy"]
Competitors & peers
- Eli Lilly (LLY) - ADHD and migraine treatments
- Shire/Takeda (TKXX) - ADHD and movement disorder products
- Neurochem Inc. - movement disorder therapies
- GlaxoSmithKline (GSK) - epilepsy and neurological treatments
- Abbott Laboratories (ABT) - seizure and neurological disorders
- Biogen (BIIB) - neuroscience-focused therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.